Study of A-101 Topical Solution for the Treatment of Common Warts

PHASE3CompletedINTERVENTIONAL
Enrollment

503

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

June 20, 2019

Study Completion Date

September 6, 2019

Conditions
Common Wart
Interventions
DRUG

A-101

hydrogen peroxide topical solution 45%

OTHER

vehicle

vehicle as a topical solution

Trial Locations (24)

19008

Aclaris Investigational Site, Broomall

19034

Aclaris Investigational Site, Fort Washington

29407

Aclaris Investigational Site, Charleston

29607

Aclaris Investigational Site, Greenville

30263

Aclaris Investigational Site, Newnan

32256

Aclaris Investigational Site, Jacksonville

33144

Aclaris Investigational Site, Miami

33180

Aclaris Investigational Site, Aventura

34470

Aclaris Investigational Site, Ocala

36608

Aclaris Investigational Site, Mobile

40241

Aclaris Investigational Site, Louisville

46256

Aclaris Investigational Site, Indianapolis

48088

Aclaris Investigational Site, Warren

55432

Aclaris Investigational Site, Fridley

71913

Aclaris Investigational Site, Hot Springs

78213

Aclaris Investigational Site, San Antonio

78660

Aclaris Investigational Site, Pflugerville

78759

Aclaris Investigational Site, Austin

89148

Aclaris Investigational Site, Las Vegas

92123

Aclaris Investigational site, San Diego

92708

Aclaris Investigational Site, Fountain Valley

99202

Aclaris Investigational Site, Spokane

02467

Aclaris Investigational Site, Chestnut Hill

07044

Aclaris Investigational Site, Verona

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY

NCT03687372 - Study of A-101 Topical Solution for the Treatment of Common Warts | Biotech Hunter | Biotech Hunter